Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XLSWN
ADC Name
SC-006
Synonyms
SC006; SC 006
   Click to Show/Hide
Organization
AbbVie, Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Phase 1
Drug-to-Antibody Ratio
2
Antibody Name
Undisclosed
Antigen Name
E3 ubiquitin-protein ligase RNF43 (RNF43)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
TTD ID
D03MBU
ChEBI ID
CHEMBL4594495
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  NCT03035279
Phase 1
An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
0.00%
Patients Enrolled
Patients with advanced metastatic or unresectable colorectal cancer.
Administration Dosage
SC-006-monotherapy, 2 to 12 ug/kg IV every 3 weeks.
Related Clinical Trial
NCT Number NCT03035279  Clinical Status Phase 1
Clinical Description An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer.
References
Ref 1 Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.